Prothena Corporation plc
25-28 North Wall Quay
Dublin
1
Tel: 353-1-902-3519
Fax: 353-1-902-3510
Website: http://www.prothena.com
Email: info@prothena.com
214 articles about Prothena Corporation plc
-
Prothena Receives FDA Fast Track Designation For NEOD001, A Monoclonal Antibody For The Treatment Of Patients With AL Amyloidosis
12/16/2014
-
GUEST COLUMN: Does Size Kill Culture? Prothena Doesn’t Think So
12/12/2014
-
Prothena Corporation plc To Present At The Oppenheimer 25th Annual Healthcare Conference In New York
12/9/2014
-
Prothena Corporation plc Targets Rare Protein-Misfolding Disease In Late-Stage Study
12/3/2014
-
Prothena Corporation plc Initiates NEOD001 Global Phase 3 Registrational Trial Based On Positive Results In Ongoing Phase 1/2 Study Of NEOD001 In Patients With AL Amyloidosis
12/3/2014
-
Prothena Corporation plc CEO Diagnosed With Pancreatic Cancer
12/3/2014
-
Prothena Corporation plc Reports Third Quarter 2014 Financial Results And R&D Progress
11/4/2014
-
Prothena Corporation plc Announces Presentation At Federation Of European Physiological Societies 2014 Congress
8/27/2014
-
Prothena Corporation plc Release: Dr. Dale Schenk To Discuss Parkinson's Disease At 2014 Rejuvenation Biotechnology Conference
8/19/2014
-
Prothena Corporation plc Reports Second Quarter 2014 Financial Results And R&D Progress
8/4/2014
-
Prothena Corporation plc Release: Initiation Of Multiple Ascending Dose Phase 1 Study Of PRX002 In Patients With Parkinson's Disease
8/1/2014
-
Prothena Corporation plc Announces Pricing Of Public Offering Of 4,750,000 Ordinary Shares
6/25/2014
-
Prothena Corporation plc Announces Proposed Offering Of Ordinary Shares
6/24/2014
-
Prothena Corporation plc To Present At The Jefferies and Co. 2014 Global Healthcare Conference In New York
5/28/2014
-
Prothena Corporation plc Reports First Quarter 2014 Financial Results And Provides R&D Updates
5/6/2014
-
Prothena Corporation plc To Host Webcast And Conference Call To Discuss Interim Phase 1 Data Of Ongoing NEOD001 Study In Patients With AL Amyloidosis On May 2
5/2/2014
-
Prothena Corporation plc Announces Appointment Of Chief Legal Officer
5/1/2014
-
Prothena Corporation plc's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses In Ongoing Phase 1 Study In Patients With Immunoglobulin Light Chain (AL) Amyloidosis
4/23/2014
-
Prothena Corporation plc Release: First Human Dosed In Phase 1 Study Of PRX002 For Treatment Of Parkinson's Disease
4/9/2014
-
Prothena Corporation plc Announces Clinical Data To Be Presented At The International Symposium On Amyloidosis
3/19/2014